Log in

NASDAQ:NLNKNewLink Genetics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$15.48
+0.33 (+2.18 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.75
Now: $15.48
$16.09
50-Day Range
$0.89
MA: $9.07
$14.10
52-Week Range
$0.82
Now: $15.48
$3.60
Volume104,770 shs
Average Volume547,540 shs
Market Capitalization$577.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Read More
NewLink Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$940,000.00
Book Value$2.11 per share

Profitability

Net Income$-42,990,000.00
Net Margins-4,592.84%

Miscellaneous

Employees55
Market Cap$577.84 million
Next Earnings DateN/A
OptionableOptionable

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of NewLink Genetics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell."
View analyst ratings for NewLink Genetics
.

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) announced its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative return on equity of 41.50%.
View NewLink Genetics' earnings history
.

Has NewLink Genetics been receiving favorable news coverage?

News headlines about NLNK stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NewLink Genetics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about NewLink Genetics
.

Who are some of NewLink Genetics' key competitors?

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Opko Health (OPK), SunPower (SPWR), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Cara Therapeutics (CARA), Alibaba Group (BABA) and Celldex Therapeutics (CLDX).

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the following people:
  • Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
  • Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
  • Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
  • Mr. Brian Wiley, Chief Commercial Officer (Age 51)
  • Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $15.48.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $577.84 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.

What is NewLink Genetics' official website?

The official website for NewLink Genetics is www.newlinkgenetics.com.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.